Symptom Burden and Unmet Supportive Care Needs in Lung Cancer Patients Undergoing First or Second Line Immunotherapy
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/17/2019 |
| Start Date: | October 16, 2016 |
| End Date: | February 1, 2019 |
Doctors are recruiting patients receiving care for lung cancer at the Wake Forest Baptist
Comprehensive Cancer Center asking about needs and experiences during immunotherapy.
Immunotherapy is a new treatment for lung cancer. The research is to better understand
patients' perspectives on what immunotherapy is like and will provide important information
to help understand the symptoms patients experience, the impact of treatment on daily life,
ways that people adapt to the challenges of treatment, and services that may help people live
better during treatment.
Comprehensive Cancer Center asking about needs and experiences during immunotherapy.
Immunotherapy is a new treatment for lung cancer. The research is to better understand
patients' perspectives on what immunotherapy is like and will provide important information
to help understand the symptoms patients experience, the impact of treatment on daily life,
ways that people adapt to the challenges of treatment, and services that may help people live
better during treatment.
The overall primary objective of this pilot study is to describe patient-reported symptom
burden, unmet supportive care needs, and use of and interest in supportive care services in
stage IV non-small cell lung cancer patients undergoing first or second line immunotherapy
and to identify psychosocial factors associated with these outcomes.
50 stage IV non-small cell lung cancer patients will be recruited through the Wake Forest
Baptist Comprehensive Cancer Center. The study team will use purposive sampling to assure
representation of patients at different stages in immunotherapy (i.e., initiating treatment,
anticipating scan results, after onset of immune-related side effects).
burden, unmet supportive care needs, and use of and interest in supportive care services in
stage IV non-small cell lung cancer patients undergoing first or second line immunotherapy
and to identify psychosocial factors associated with these outcomes.
50 stage IV non-small cell lung cancer patients will be recruited through the Wake Forest
Baptist Comprehensive Cancer Center. The study team will use purposive sampling to assure
representation of patients at different stages in immunotherapy (i.e., initiating treatment,
anticipating scan results, after onset of immune-related side effects).
Inclusion Criteria:
- Histologically or cytologically confirmed stage IV (per AJCC 7th edition) non-small
cell lung cancer.
- Receiving first or second line immunotherapy.
- ECOG Performance status of 0-3.
- English-speaking
Exclusion Criteria:
- Unable to provide informed consent
We found this trial at
2
sites
Click here to add this to my saved trials
1 Medical Center Blvd
Winston-Salem, North Carolina 27157
Winston-Salem, North Carolina 27157
336-716-2011
Wake Forest University Health Sciences Welcome to Wake Forest Baptist Medical Center, a fully integrated...
Click here to add this to my saved trials